|23rd November 2020||Jian Xie||6,000||Open or private sale||$44.08||$264,480.00|
|20th November 2020||Jian Xie||1,000||Open or private sale||$42.50||$42,500.00|
|1st November 2020||Jian Xie||504||Payment by withholding||$32.53||$16,395.12|
|30th September 2020||Ming Hsieh||448||Exercise of derivative||$0.00|
|15th September 2020||Hanlin Gao||467,659||Other acquisition or disposition||$0.00|
|11th September 2020||Jian Xie||150,000||Other acquisition or disposition||$0.00|
|2nd September 2020||Paul Kim||425||Open or private sale||$28.32||$12,034.56|
|28th August 2020||Jian Xie||441||Open or private sale||$30.82||$13,590.96|
|19th August 2020||Paul Kim||25,407||Open or private sale||$44.16||$1,122,039.18|
|17th August 2020||Paul Kim||100,000||Open or private sale||$41.47||$4,146,920.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 4/10.
Fulgent Genetics, Inc. was founded on May 13, 2016 and is headquartered in Temple City, CA. Its technology platform includes proprietary gene probes, advanced database algorithms, adaptive learning software and proprietary laboratory information management systems.